New technique developed by UAlberta researchers vastly improves precision of gene-editing technology.
Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each cell and edits in the correct information with precision accuracy.
It’s called gene editing, and University of Alberta researchers have just published a game-changing study that promises to bring the technology much closer to therapeutic reality.
“We’ve discovered a way to greatly improve the accuracy of gene-editing technology by replacing the natural guide molecule it uses with a synthetic one called a bridged nucleic acid, or BNA,” said Basil Hubbard, Canada Research Chair in Molecular Therapeutics and an assistant professor in the U of A’s Department of Pharmacology, who led the study.
He and his team have filed a patent on their discovery and are hoping to partner with the pharmaceutical industry to incorporate it into a therapeutic.
Interest in gene-editing technology has been rapidly rising since the discovery of CRISPR/Cas9. This system is naturally present in bacteria, which use it for protection against their natural predators, called bacteriophages.
“It allows bacteria to store information about previous infections and then use it to seek out and destroy the DNA of new invaders by cutting it,” explained Hubbard.
“What researchers have realized is that this system can be programmed to cut a specific DNA sequence in a human cell also, allowing us to edit our genes. One of the main issues, however, is that the system is not perfectly specific—sometimes it cuts a similar but incorrect gene.”
Using its natural RNA guide molecule, the Cas9 system is quite accurate, only making a mistake about one per cent of the time, he noted.
“However, given that there are trillions of cells in the human body, even one percentage off is quite significant, especially because gene editing is permanent. One wrong cut and a patient could end up with a serious condition like cancer.”
The new BNA guide molecule that Hubbard and his team—which includes PhD student Christopher Cromwell, who is first author on the study—developed was shown to be much more stable and stringent in its quest for finding the right DNA to cut.
“Our research shows that the use of bridged nucleic acids to guide Cas9 can improve its specificity by over 10,000 times in certain instances—a dramatic improvement,” said Hubbard.
Though gene-editing technology still has several hurdles to overcome, including the challenge of how to deliver it effectively into the human body, it may someday be used to treat a wide variety of genetic diseases, from muscular dystrophy to hemophilia and various cancers.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Biotech Cos. Must Respect Coexisting Gene Editing Patents on September 18, 2018 at 11:53 am
A legal dispute over the fundamental patent rights to CRISPR-Cas9 gene editing technology might be coming to an end. On Monday, Sept. 10, the U.S. Court of Appeals for the Federal Circuit affirmed the ... […]
- Why the Gene Editors of Tomorrow Need to Study Ethics Today on September 18, 2018 at 3:00 am
October 2018. Subscribe to WIRED. Two years after biochemist Jennifer Doudna helped introduce the world to the gene-editing tool known as Crispr, a 14-year-old from New Jersey turned it loose on a pet... […]
- These Companies Want to Combine Stem Cells and CRISPR Gene Editing to Treat Diabetes on September 17, 2018 at 2:38 pm
Some news from the land of CRISPR gene-editing to start off this week: The appropriately named CRISPR Therapeutics—a biotech that, it should be noted, was co-founded by Dr. Emmanuelle ... […]
- CRISPR gene editing creates cocaine-proof mice, aims to crack addiction puzzle on September 17, 2018 at 2:04 pm
Gene editing has already given us malaria-resistant mosquitoes and heat-resistant cows. Now, researchers from the University of Chicago may have topped both of those feats with their latest creation: ... […]
- This Gene-Editing Biotech Toppled On A Deal In Diabetes on September 17, 2018 at 12:12 pm
Crispr Therapeutics (CRSP) stock toppled Monday after the biotech announced a collaboration deal with privately held ViaCyte to work on a gene-edited diabetes treatment. ViaCyte is working on a diabet... […]
- Editing in a yield increase on September 17, 2018 at 2:06 am
The promise of gene editing to boost crop performance is real. The key is finding which genes that can be turned on or off will help reach the desired result. There’s success for editing soybeans for ... […]
- Rice gene editing research cited as among world-changing science on September 14, 2018 at 6:17 am
Research published by a University of Arkansas System Division of Agriculture scientist has been recognized by an international publisher for its high-impact potential. Vibha Srivastava, professor of ... […]
- Gilead Inks Gene Editing Collaboration Deal for HBV Infection on September 13, 2018 at 9:04 am
Gilead Sciences, Inc. GILD announced that it has entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV ... […]
- Kansas Wheat Commission to fund gene editing research at Kansas State University on September 12, 2018 at 7:35 am
The Kansas Wheat Commission has announced that it is putting its support behind a technology being advanced at Kansas State University and that one researcher says will bring “many new discoveries” in ... […]
via Bing News